FY2025 · ended Dec 31, 2025 · Revenue $4.05M, +115.6% YoY · Filed Mar 26, 2026
Insight Molecular Diagnostics Inc. (IMDX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.1 million and a net loss of $50.2 million. Free cash flow was -$25.4 million. As of Jun 30, 2026 it held $17.8 million in cash and investments and $2.4 million in total debt.
Revenue (TTM)
$1.67M
-60.8% vs year-ago TTM
Net income (TTM)
$-49.36M
+22.2% vs year-ago TTM
Operating cash flow (TTM)
$-27.08M
-18.3% vs year-ago TTM
Free cash flow (TTM)
$-31.00M
-30.0% vs year-ago TTM
EPS (TTM)
$-1.46
+49.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
32.17M
+12.5% vs prior year
Net cash
$15.31M
as of Jun 30, 2026
Operating margin
-3011.9%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | -$64.1M |
| Diluted EPS | -$1.65 | -$4.66 | -$3.75 | — | — |
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M |
| Stockholders' equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M |
| Cash and investments | $11.6M | $8.6M | $9.4M | $20.0M | $32.9M |
| Total debt | $3.3M | $3.6M | — | $117,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 21, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 688 Insight Molecular Diagnostics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.